Bio-NN
Description:
Bio-NN Nanoparticle Controlled-Release Injectable DDS Technology
Bio-NN Nanoparticle Controlled-Release Injectable DDS technology is using liposome-encapsulated or albumin-bound drugs for prolonged bio half-life, better targeted delivery & reduced toxicity.
Selective Tumor Targeting Achieved by Bio-NN DDS via the Enhanced Permeation and Retention (EPR) Effect
- Due to its large molecular size, the liposome-encapsulated anti-cancer drug administered intravenously escapes renal clearance. It cannot penetrate the tight endothelial junctions of normal blood vessels, but can extravasate in tumor vasculature and become trapped in the tumor vicinity. Therefore, its intra-tumor concentration will build up due to lack of efficient lymphatic drainage in solid tumor.
- The solid tumor shows disorganized and leaky vasculature of 200 to 800 nm due to its rapid growth, while normal tissue has tight space of ~ 2 nm. The Bio-NN DDS is designed to exhibit apparent sizes of 30 to 150 nm.
- Tumor vascular permeability is, therefore, important in designing highly selective targeting delivery of macromolecular anti-cancer drugs for tumors.
Bio-PEG Pegylation Liposome-Encapsulated Injection
- Prolonged Circulating Half-Life: e.g., GCSF (2 – 4 hours) to PEG-GCSF (16-80 hours)
- Improved Solubility
- Reduced Immunogenicity, Antigenicity and Toxicity
- Reduced Proteolytic Degradation
- Improved In-vivo Stability
- Less Frequent Administration: Improved Patient Compliance
Pegylated Liposome Injection
- Reinforced Passive Targeting for Solid Tumors
- Prolonged Action
- Improved Solubility
- Improved In-vivo Stability
- Reduced Toxicity
Ligand-Mediated Pegylated Liposome Injection
- Tumor Targeting
- Prolonged Action
- Improved Solubility
- Improved In-vivo Stability
- Reduced Toxicity
Albumin-Bound Drug Nanoparticle Injection
- Prolonged Action
- Improved Solubility
- Improved In-vivo Stability
- Reduced Toxicity
- Increased Bioavailability
